



Secondary patenting on the rise

Share of drugs with non-AI patent by approval cohort




Nominal patent life by approval cohort




So are patent challenges

Share of drugs with challenge
by approval cohort




Patent challenges focus on secondary patents



Share of drugs challenged within 3 years eligibility
By portfolio characteristics



Share of patents challenged
By patent type



When secondary patents litigated to completion, generics usually win



Secondary (non-AI) patents disproportionately boost patent term for non-NCEs

Increment to patent term from secondary patents (by drug type)

Author calculation - based on 485 drugs from Hemphill Sampat JELS sample

